Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
China SXT Pharmaceuticals, Inc. (SXTC)
USD2.45
-0.01 (-0.41%)
CN NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
Address
178 Taidong Road North 225300
Taizhou, ZJ, CN
Taizhou, ZJ, CN
CEO
Feng Zhou
Website
sxtchina.com
IPO
2019-01-04
CIK 1723980 ISIN VGG2161P1650
Description
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Taizhou, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.45
-0.01 (-0.41%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
70.1K
Beta
1.89
Float Shares
684.9K
Free Float %
88.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +7.05% | +0.60% | -18.93% | -26.75% | -99.23% | -99.30% | -99.16% | -99.78% | -99.97% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
2.45
DCF (Unlevered)
35.79
+1,361.0%
DCF (Levered)
38.15
+1,457.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Quality scores
Altman Z-Score
-1.06
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-38.4% Q1'26: +163.0% (vs Q4'24)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-11.6% Q1'26: +133.3% (vs Q4'24)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-891.6% Q1'26: -189.0% (vs Q4'24)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-664.1% Q1'26: -65.4% (vs Q4'24)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-268.6% Q1'26: -70.9% (vs Q4'24)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+68.3% Q1'26: -60.8% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.16× Q1'26: -0.42× (vs Q4'24)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-2.59M
OE per share TTM
-4.31
Owner's Yield
-63.48%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
36.8%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
3
Total invested
131.3K
Insider transactions (90d)
0
Beneficial owners (>5%)
11
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Hudson Bay Capital Management LP | 2.74M | 9.99% | — | 2.74M | — | — | PN | State of Delaware | 2020-02-07 | ↗ |
| 2 | Sander Gerber | 2.74M | 9.99% | — | 2.74M | — | — | IN | State of Delaware | 2020-02-07 | ↗ |
| 3 | S | 2.67M | 9.99% | 2.67M | — | 2.67M | — | CO | Cayman Islands | 2020-02-14 | ↗ |
| 4 | Jeff Easton | 2.58M | 9.90% | 2.58M | — | 2.58M | — | IN | Delaware | 2022-01-21 | ↗ |
| 5 | Lind Global Fund II LLC | 2.58M | 9.90% | 2.58M | — | 2.58M | — | OO | Delaware | 2022-01-21 | ↗ |
| 6 | Lind Global Fund II LP | 2.58M | 9.90% | 2.58M | — | 2.58M | — | PN | Delaware | 2022-01-21 | ↗ |
| 7 | Waqas Khatri | 2.00M | 7.50% | 2.00M | — | 2.00M | — | IN | Pakistan | 2019-05-08 | ↗ |
| 8 | John M. Fife | 1.04M | 9.99% | 1.04M | — | 1.04M | — | IN | — | 2023-03-29 | ↗ |
| 9 | Streeterville Capital LLC85-2954598 | 1.04M | 9.99% | 1.04M | — | 1.04M | — | OO | — | 2023-03-29 | ↗ |
| 10 | Streeterville Management LLC85-3223919 | 1.04M | 9.99% | 1.04M | — | 1.04M | — | OO | — | 2023-03-29 | ↗ |
| 11 | Forsakringsaktiebolaget Avanza Pension | 28.7K | 5.00% | 28.7K | — | — | — | FI | Stockholm, Sweden | 2024-02-09 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
3
+3 vs prev Q
New positions
3
Closed positions
0
Increased
3
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | SABBY MANAGEMENT, LLC | 78.2K +78.2K (+100.0%) | 131.3K +131.3K (+100.0%) | 19.35% +19.353 pp | 0.29% +0.291 pp | USD1.68 +0.0% | 1 qtrs NEW |
| 2 | CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | 1.00 +1.0 (+100.0%) | 2.00 +2.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.00 +68.0% | 1 qtrs NEW |
| 3 | UBS GROUP AG | 1.00 +1.0 (+100.0%) | 2.00 +2.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.00 +68.0% | 1 qtrs NEW |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-01-20 | Simon Lim Sze Beng | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-01-20 | Chee Yong Lip | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-05-10 | Liu Tong Tony | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-01-31 | Pan Xiaodong Sean | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-05-22 | Ji Xiaodong | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-12-31 | Zheng Jun | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-07-04 | Zhou Feng Felix | Director / Officer | — | — | Class B Ordinary Shares | 0 | 0.00 | — | 4 | I | ↗ |
Executive team
Top executives
EBIT / Employee
-950.00
Shares Outstanding
773.5K
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Feng Zhou | Chairman of the Board & Co-CEO | 50.0K | male |
| Xiaodong Pan | Chief Financial Officer | 50.0K | male |
| Jun Zheng | Executive Director | — | male |
| Sze Beng Lim | Co-Chief Executive Officer | — | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SXTC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
